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thermore, FC and HC differ in valuation of both volume
and price. Apart from the differences between FC and
HC, neither method takes account of disablement. Many
patients were disabled at the start of the study, and in the
majority of cases, disablement was due to BPD. FC does
not take these costs into account. Although HC is poten-
tially able to value the costs of disablement, this is cur-
rently not the practice in RCTs. However, production
losses associated with disablement are considerable. In
addition, neither FC nor HC provides an answer to the
question what calculations to perform when a person
recovers from disablement and resumes work.
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OBJECTIVES: Frequency of adverse events -AEs- related
with antipsychotics usage is high. Along with clinical
implications, economic impact might be important. A
pharmacoeconomic model has been developed to ascer-
tain the economic impact of patients experiencing these
AEs. The purpose of this study was to model the eco-
nomic consequences of AEs related with current antipsy-
chotics in Spain. METHODS: A cost-effectiveness model
was developed using a Markov modeling approach sim-
ulating treatment of a cohort of schizophrenics for 12
months, initiating treatment with one of four antipsy-
chotic drugs; haloperidol, risperidone, olanzapine and
ziprasidone. The model assumes equivalent efﬁcacy
among the antipsychotics. Conditional probabilities of
developing any of four adverse events was calculated.
Treatment was modiﬁed (decrease dose, switch medica-
tion) according to incidence of AEs and physician judg-
ments, obtained from a local cross-sectional study and
clinical trials previously published. The analysis was con-
ducted in year 2002 from a 3rd party payer perspective
(only direct medical cost are computed). Results are
shown as annual cost per month with psychotic symp-
toms controlled. Univariate sensitivity analysis was per-
formed. RESULTS: The therapeutic strategy starting with
Ziprasidone showed the most favorable cost-effectiveness
ratio, being the dominant option (showing the lower costs
and the greater number of months with symptoms con-
trolled), versus the other options considered. The annual
cost per patient per month with symptoms controlled was
€1.035 with that of ziprasidone, versus €1.084, €1.087,
and €1.090 with haloperidol, risperidone and olanzapine,
respectively. Results are robust to one-way sensitivity
analysis. CONCLUSIONS: Adverse events related with
the usage of antipsychotic drugs produce a considerable
economic impact. Availability of drugs with similar effec-
tiveness but better tolerability than existing agents,
should positively impact on clinic aspects of schizophre-
nia and health care budgets as well.
PMH13
AFFECTIVE PSYCHOSES IN ADOLESCENTS:THE
ECONOMIC CONSEQUENCES OF ACUTE CARE
HOSPITAL ADMISSIONS OVER THREE YEARS
O’Brien JA, Pitoniak-Morse CA, Caro JJ
Caro Research Institute, Concord, MA, USA
OBJECTIVE: Although affective psychoses are usually
associated with adults, it has been reported that at any
given point in time approximately 5% of children and
adolescents in the U.S. general population suffer from
depression. This study sought to identify adolescents
(10–19 years) requiring acute hospital management in
1998 for affective psychoses, their readmissions for these
problems over a 3-year period and the resulting costs.
METHODS: The index admission was identiﬁed in the
1998 Massachusetts all payer hospital database using
ICD-9 diagnosis codes. Suicide attempts were identiﬁed
by E codes. Readmissions were tracked over three years
(1998–2000) by means of a unique patient identiﬁer. All
accommodations, ancillaries and physician services were
included in the cost estimates, which were adjusted for
medical inﬂation, national values, cost-to-charge ratios,
and reported in 2003 US$. RESULTS: A cohort of 890
patients was identiﬁed with 26% coded as bipolar; 12%
admitted due to intentional self-harm. Mean age was 16.4
years (22% = 10–14 years, 78% = 15–19 years); 45%
were male. Index admission mean length of stay was 8.5
days (range: 1–106); 68% spent time in a psychiatric unit.
Mean cost per stay was $7,239 (range: $491–$107,747).
All survived the hospital stay. At discharge, 5% were
transferred to mental health facilities (MHF). Subsequent
to index admission, 25% were readmitted at least once
(mean 1.5, range: 1–11) within 3 years for affective psy-
choses or self-harm and all survived to discharge. The
cumulative 3-year hospital cost for study-relevant admis-
sions for the cohort was estimated at $9.1 million. CON-
CLUSIONS: One quarter of adolescents with affective
psychoses who require acute hospital management can 
be expected to incur additional disorder-related hospital
costs within three years. The estimates, albeit conserva-
tive, as outpatient therapy and MHF care were not
included, illustrate the economic consequences of these
disorders for this age group.
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OBJECTIVE: To assess the prevalence and burden of
ADHD in the Nordic countries. METHODS: Literature
databases were searched for publications relevant to the
study countries and keywords. The time frame was 1987
to 2002. The keywords were ADHD, DAMP, MBD, and
HKD. RESULTS: There were six prevalence studies in
children aged between six and nine years. The prevalence
rates of DAMP ranged between 2.8 and 7.1%. The preva-
lence rates of ADHD ranged between 3.7 and 7.1%.
Several smaller Finnish studies reported that children 
with MBD/ADHD often transfer to special education, 
or require additional teaching at school. Finnish and
Swedish studies found that 75–80% of children with
MBD/ADHD don’t complete high school. One Swedish
study showed that 11% of children with ADHD had full
sick pension at age 22. Finnish and Norwegian pub-
lications report that 38%–47% of children with
ADHD/MBD have no friends. Fifty-three percent of the
parents in a Norwegian study said their marital problems
were associated with the child’s MBD. Finnish and Nor-
wegian studies found that the child’s dysfunction caused
the family extra burden in daily activities and a change
of their work situation or time. Swedish, Danish, and
Finnish studies have shown that ADHD is associated with
long-term psychiatric consequences. In Denmark, 24% of
children with ADHD had been given a lifetime psy-
chiatric diagnosis at age 23. Finnish, Norwegian, and
Swedish studies have reported an over-representation 
of ADHD in prison populations. Moreover, children with
ADHD are especially exposed to sexual offences, and
commit such crimes more often than others. CONCLU-
SIONS: The Nordic data on prevalence of ADHD is in
concordance with international ﬁgures. Although some 
of the studies were small and not randomised, the 
results indicate that ADHD is associated with a great
burden for the affected children, their families, and the
environment.
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Compliance to treatment is a key success factor to reduce
hospitalisations in schizophrenic patients. Conventional
antipsychotics (e.g., haloperidol) are effective in reduc-
ing positive symptoms of schizophrenia, and can cause 
multiple side effects (extrapyramidal symptoms, tardive
dyskinesia). Atypical antipsychotics with daily oral
administration (risperidone, olanzapine, clozapine) show
improved efﬁcacy and tolerability compared to con-
ventional neuroleptics. Conventional depots have been
shown to increase compliance and reduce the risk of
relapse over oral conventional treatments. Long-acting
risperidone (LA-RIS), administered intramuscularly once
every two weeks, is the ﬁrst to combine the beneﬁts of a
long-acting formulation with those of an atypical antipsy-
chotic. OBJECTIVE: To assess cost-effectiveness of 
LA-RIS versus oral olanzapine (OLA) and haloperidol
decanoate (HAL-D) in recently diagnosed schizophrenic
patients in the perspective of the Italian National Health
care System (NHS). METHODS: A French decision tree
model was adapted to the Italian setting: outcome prob-
abilities and cost estimates were based on published 
data, and supplemented with expert opinion. Only direct
medical costs were considered. For LA-RIS (not yet mar-
keted in Italy), 3 different price hypotheses were tested
(€100–125–150/injection q2weeks). Effectiveness mea-
sures were relapse-free patients and patients maintained
on the same treatment for 2 years. RESULTS: LA-RIS was
found dominant versus HAL-D in all three hypotheses
tested. Versus OLA (10mg/day), LA-RIS cost-
effectiveness ratios ranged from dominance to a
maximum of €17,544/2 years per incremental relapse-free
patient. Sensitivity analysis showed that results were
robust over a wide range of parameters tested, including
variation of the daily dose of OLA to account for current
medical practice in Italy according to the results of the
RODOS papers (13.5mg/day). CONCLUSIONS: The
model indicates that in recently diagnosed patients, 
LA-RIS is cost-saving versus HAL-D and cost-saving/
cost-effective vs. OLA and should be preferred as a treat-
ment option over oral atypicals and conventional depots,
in the perspective of the Italian NHS.
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OBJECTIVES: The occurrence of dyslipidemia, glucose
intolerance and weight gain may lead to an increased 
risk for developing Diabetes and coronary heart disease
(CHD) during therapy with atypical antipsychotics. These
complications directly inﬂuence an antipsychotic agent’s
cost-effectiveness. One method for outcome assessment is
to capture these effects with the combined endpoint of
metabolic syndrome (MetS) and, using epidemiological
